Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002314 · ClinicalTrials.gov registry record · Phase 2
A Study of Ro 24-7429 in Patients With HIV-Related Kaposi's Sarcoma
A Phase 2 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00002314: Completed Phase 2 study, sponsored by Hoffmann-La Roche.
NCT00002314 is a Phase 2 study that has completed, run by Hoffmann-La Roche. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002314, a Phase 2 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
To study the effects of Ro 24-7429 on tumor growth in patients with HIV-related Kaposi's sarcoma. To study the safety and tolerance, effects on HIV replication, and immunologic effects of Ro 24-7429 in this patient population. To explore relationships between exposure to Ro 24-7429 and its metabolites with its antitumor and antiviral activities and drug toxicity.
Interventions
- DRUG Ro 24-7429
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 2 |
What the finished NCT00002314 record still lists
NCT00002314 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which Ro 24-7429 is the first listed.
NCT00002314 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002314 about?
NCT00002314 is a clinical study titled "A Study of Ro 24-7429 in Patients With HIV-Related Kaposi's Sarcoma". To study the effects of Ro 24-7429 on tumor growth in patients with HIV-related Kaposi's sarcoma. To study the safety and tolerance, effects on HIV replication, and immunologic effects of Ro 24-7429 in this patient population. To explore relationships between exposure to Ro 24-7429 and its metabolit...
What is the current status of trial NCT00002314?
This trial is currently completed. It is a Phase 2 study.
What interventions are being tested in trial NCT00002314?
The interventions under investigation include: Ro 24-7429 (DRUG).
Who is sponsoring clinical trial NCT00002314?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.